Webinar: Developing Lentiviral Vectors for ex vivo and in vivo Gene Therapy
Optimizing the safety of lentiviral vectors has been one of the main focal points of lentiviral vector development. Likewise, the design of the lentiviral backbone and the therapeutic payload cassette can influence the manufacturability of the particles, for example their quality and potency features. Optimizing those features will further improve the safety and efficacy profile of future ex vivo and in vivo gene therapies.
To date the safety of over 25 lentivirus backbones has been tested in more than 200 clinical trials. SIRION Biotech will discuss the main features of those backbones and the main strategies to further optimize their safety. We will also give insights into datasets from our Viral Vector Know-How Hub to illustrate how payload design strategies can affect the manufacturability of the lentiviral particles and their usage to develop ex vivo and in vivo gene therapies. Our Viral Vector Know-How Hub includes data derived from over 6,000 lentiviral vectors.
We will also present a complementary strategy to optimize cell transduction by using LentiBOOST®, a chemical transduction enhancer currently used in more than 20 Phase I/II and III clinical trials, as part of developing a cGMP-compliant process to manufacture CD19-CAR T cells.
For more information about the Webinar, and to sign up to attend, please visit https://www.sirion-biotech.com/…
SIRION Biotech was founded in 2005 to lead the next generation of viral vector technologies for gene and cell therapy as well as vaccine development. Now SIRION offers one of the world’s most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses to expedite gene therapy research and advance drug development. SIRION is becoming a partner of choice in this growing sector. LentiBOOST® has been used in a number of clinical trials from early stage clinical Phase 1/2 through late stage clinical Phase 3 trials and demonstrated clinical success in improving transduction of the therapeutic vector.
SIRION BIOTECH GmbH
Am Klopferspitz 19
82152 Martinsried
Telefon: +49 (89) 70096199-9
Telefax: +49 (89) 70096199-8
https://www.sirion-biotech.de
Head of Marketing
Telefon: +49 (89) 70096199-53
E-Mail: crowe@sirion-biotech.com